Overview of WinRho

Property	Description
Active Ingredient	Rho(D) Immune Globulin (Human)
Form	Sterile solution or lyophilized powder for injection
Pharmacological Class	Immune Globulin, Anti-D Globulin
Common Use	Prevention of immune sensitization
Origin	Human plasma-derived

What Type of Medicine is Rho(D) Immune Globulin?

Rho(D) Immune Globulin (Human), known by the brand name WinRho SDF, is classified as a highly specific biological product and an immunizing agent within the immune globulin pharmacological class. This medicine is a preparation of polyclonal antibodies—protective proteins of the Immunoglobulin G (IgG) class—which specifically target the Rho(D) antigen. It is derived exclusively from purified, sterile human plasma obtained from screened donors. This origin means the product delivers passive immunity, supplying necessary antibodies directly instead of stimulating the patient's body to generate its own long-term immune defense.

The Active Component and Its Form

The medicine's active constituent is the Rho(D) Immune Globulin (Human), an antibody preparation also known as anti-D immunoglobulin. WinRho SDF is typically differentiated by its manufacturing process, which includes specialized virus filtration to enhance product safety. The product is supplied as either a sterile liquid solution for injection, stabilized by components like maltose in certain formulations, or as a lyophilized powder requiring reconstitution. This robust formulation allows it to be safely delivered via either Intravenous (IV) injection for rapid systemic effect or Intramuscular (IM) injection, depending on specific clinical needs.

General Purpose: Preventing Immune Sensitization

The overarching purpose of administering Rho(D) Immune Globulin is to prevent the patient's immune system from initiating a damaging, lasting immune response to foreign blood components carrying the Rho(D) antigen. This therapeutic action is achieved through Antibody-Mediated Immunosuppression, where the injected antibodies rapidly bind to and clear the foreign cells. This preventive measure is universally employed in scenarios where an Rh-negative individual is exposed to Rh-positive red blood cells—such as during certain stages of pregnancy. By preemptively neutralizing and eliminating these components, the medicine provides the crucial, well-established benefit of suppressing the formation of long-term memory antibodies, thereby preventing severe immune conflicts in the future.

Regulatory References

NIH pharmacological studies

What side effects are possible with WinRho?

Possible Side Effects and Safety Information

Rho(D) Immune Globulin (Human) has an officially documented safety profile characterized by a range of adverse reactions, which are formally classified by frequency and grouped into System-Organ Classes in regulatory documents.

Reactions categorized as Very Common in official labeling include headache, chills, and pyrexia (fever). Other officially documented effects are local injection site reactions, nausea, and dizziness, which are often classified as less frequent.

Serious Adverse Reactions and Safety Constraints

The regulatory profile identifies several serious, clinically significant adverse reactions. For the treatment of Immune Thrombocytopenic Purpura (ITP), Intravascular Hemolysis (IVH) is a critical safety concern, noted in prescribing information as potentially leading to severe complications such as acute renal failure, Disseminated Intravascular Coagulation (DIC), and, rarely, death. Anaphylactic reactions and generalized severe hypersensitivity are also documented serious risks.

Official labeling notes time-related patterns, stating that signs of severe IVH often appear within 4 to 8 hours following administration in ITP patients.

Population-specific safety considerations are documented for older adults, who may be at an increased risk for complications if IVH develops. Similarly, patients with a known IgA deficiency who possess anti-IgA antibodies have an officially stated elevated risk of severe hypersensitivity. Additionally, as a plasma-derived product, the medicine carries a theoretical risk of transmitting infectious agents, a constraint noted in all regulatory documents for such products.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Rho(D) Immune Globulin (Human) is primarily associated with dosage miscalculation, such as the confusion between International Units (IU) and micrograms (mcg). High doses, especially those administered during Immune Thrombocytopenic Purpura (ITP) treatment, are linked to an elevated risk of severe, life-threatening reactions.

Documented Manifestations and Severe Outcomes The principal and most severe risk documented in regulatory labels is Intravascular Hemolysis (IVH). Initial signs of IVH may include fever, back pain, shaking chills, and discolored urine or hematuria. If not managed, IVH can rapidly progress to severe complications, including acute renal insufficiency, multi-system organ failure, Disseminated Intravascular Coagulation (DIC), and fatal outcome has been reported. Severe systemic reactions, including anaphylaxis, are also documented risks that require prompt attention.

Emergency Response and Monitoring Immediate medical attention must be sought if symptoms of anaphylaxis (e.g., difficulty breathing, swelling) occur. Any manifestation of IVH, such as fever, back pain, or red/brown urine, requires urgent evaluation. For patients undergoing ITP treatment, regulatory mandates require close monitoring in a healthcare setting for at least eight hours following administration to watch for these hemolytic signs. Individuals of advanced age and those with pre-existing renal conditions are officially noted to be at an increased risk for severe outcomes following overdose-related events.

Therapeutic Uses of WinRho

What WinRho Treats: Main Uses and Benefits

WinRho (Rho(D) Immune Globulin) is commonly used to provide targeted supportive therapeutic benefit across two distinct clinical domains, focusing on either preventing a critical immune reaction or providing symptomatic support in acute conditions.

This medication is primarily relevant for easing the potential burden of severe blood disorders in future newborns by addressing Rh-negative immune sensitization and is also used for managing the distressing symptomatic manifestations of Immune Thrombocytopenic Purpura (ITP). It is applied in clinical settings that involve acute or unstable symptom patterns, such as during phases of low platelet counts.

“The application of WinRho supports multiple symptom-focused domains and helps maintain a sense of stability when symptoms are more noticeable.”

Quick Fact: Relief for Acute Symptomatic Episodes

This treatment is used when symptoms create noticeable physiological strain and may assist with short-term symptomatic assistance, supporting the patient during difficult episodes linked to a bleeding risk associated with ITP.

Preventing Rh-Negative Immune Sensitization

This medication is primarily used to provide a protective benefit to Rh-negative individuals, most commonly pregnant mothers, who have been exposed to Rh-positive red blood cells. This essential prophylactic use contributes to easing the potential symptom burden of severe blood disorders (like Hemolytic Disease of the Fetus and Newborn) in future newborns, and supports the patient during difficult episodes by easing distress.

Managing Acute Symptomatic Episodes in ITP

WinRho is also applied in hematological settings to help manage the distressing symptomatic manifestations of ITP, a condition characterized by dangerously low platelet counts. It is used during acute symptomatic episodes to address low platelet levels. This may assist with short-term symptomatic assistance and offers supportive relief by helping to ease the challenging symptoms and the discomfort associated with a bleeding risk.

Regulatory References

Rh incompatibility: MedlinePlus Medical Encyclopedia

Eligibility and Restrictions for Use

Who Can and Cannot Use WinRho: Official Regulatory Information

The eligibility for WinRho (Rho(D) Immune Globulin) is strictly defined by official regulatory labeling, differentiating between its two main applications: Rh isoimmunization prophylaxis and Immune Thrombocytopenic Purpura (ITP) treatment.

Contraindicated Populations

WinRho is absolutely contraindicated in patients with a history of severe hypersensitivity to human immune globulins, including those with IgA deficiency and pre-existing anti-IgA antibodies. For Rh prophylaxis, it must not be used in infants or in Rho(D)-negative individuals who are already sensitized (i.e., have anti-D antibodies). For ITP treatment, it is contraindicated in patients with pre-existing hemolysis or autoimmune hemolytic anemia (AIHA).

Eligibility by Status and Age

Population Group	Eligibility Status
Rh Prophylaxis	Restricted to non-sensitized, Rho(D)-negative individuals.
ITP Treatment	Restricted to Rho(D)-positive, non-splenectomized children and adults.
Pregnancy	Permitted for the labeled prophylaxis indication.

Use requires special caution in older adults and ITP patients with low hemoglobin levels (below 8 g/dL), as alternate therapies may be advised. The label also requires cautious use in patients with underlying cardiac, renal, or hepatic co-morbidities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes the officially documented interaction patterns for Rho(D) Immune Globulin (Human), based strictly on regulatory sources. Interactions are primarily categorized as pharmacodynamic interference and excipient-based diagnostic interference.

Pharmacodynamic Interactions

Rho(D) Immune Globulin may impair the effectiveness of certain live virus vaccines (e.g., rubella, measles) through a pharmacodynamic interaction. This is due to the passively transferred antibodies potentially blunting the immune system's active response to the vaccine. To manage this potential impairment of efficacy, regulatory labeling requires specific timing separation.

Timing and Procedural Restrictions

Constraint Type	Official Regulatory Statement
Vaccine Timing Rule	Live virus vaccines should generally be delayed until 3 months (12 weeks) after the final dose of Rho(D) Immune Globulin.
Administration Restriction	The product must not be mixed with other medicinal products when prepared for injection or infusion.
Population Note	Vaccination of rubella-susceptible women postpartum should not be delayed due to the medicine’s receipt, representing a specific exception to the general timing rule.

Interaction with Diagnostic Products

An excipient present in the liquid formulation, maltose, can interact with certain blood glucose testing systems. This interaction may result in falsely high blood glucose readings when the testing system uses the glucose dehydrogenase pyrroloquinolinequinone (GDH-PQQ) method. This official restriction requires avoidance of such testing devices.

Mechanism of Action

How WinRho Works

WinRho is composed of purified Immunoglobulin G (IgG) antibodies that exhibit high specificity for the D antigen, a protein expressed on the surface of Rh-positive red blood cells (RBCs). Upon administration, these anti-D antibodies bind rapidly to any circulating foreign Rh-positive RBCs, forming stable antibody-antigen immune complexes on the cell surface.

This binding step mediates the subsequent clearance cascade. The antibody-coated Rh-positive RBCs are recognized by Fc gamma receptors (FcgammaR) located primarily on macrophages and other cellular components of the reticuloendothelial system, predominantly within the spleen. The resulting FcgammaR engagement triggers the phagocytic pathway, leading to the rapid engulfment and removal of the antibody-bound red blood cells.

This process, termed RBC opsonization and clearance, acts as a form of immune modulation on a systemic level. By intercepting and masking the D antigen and facilitating the prompt destruction of foreign cells, the mechanism prevents the recipient's immune system from detecting the antigen. This suppression interferes with the activation of T-cells and B-cells, thereby inhibiting the formation of long-lasting, endogenous anti-D alloantibodies.

Dosage and Administration Information

WinRho (Rho(D) Immune Globulin) is administered via injection, and its route of administration is strictly dependent on the intended use. For the treatment of Immune Thrombocytopenic Purpura (ITP), the medicine must be administered through the intravenous (IV) route only. For Rh Prophylaxis, either IV or intramuscular (IM) injection is approved.

Dosing protocols are determined by the clinical scenario. Prophylactic use typically follows fixed-dose regimens, such as 1500 IU (300 µg) given routinely during the antenatal period or postpartum within a 72-hour window following delivery of an Rh-positive infant. In contrast, treatment for ITP requires a weight-based regimen, starting typically at 250 IU/kg (50 µg/kg). This approach includes an official modification that specifies a reduced starting dose (125 to 200 IU/kg) for patients with specific hemoglobin levels (8 to 10 g/dL).

The administration also follows specific procedural requirements. If the lyophilized powder form is used and dilution is needed for IV administration, only Normal Saline is the approved diluent; the use of Dextrose in Water (D5W) is prohibited. The IV infusion for ITP is typically administered over a short period, such as 3 to 5 minutes. Additionally, the medicine must be brought to room temperature before use and given separately from other drugs. Subsequent dosing for ITP is intermittent and based on the required clinical response.

Recent Clinical Evidence

Research Overview: WinRho (Placeholder Content)

Research has explored the role of this treatment in conditions involving certain blood component interactions. Studies have focused on examining outcomes related to the management of these specific immune-related conditions in both adult and pediatric populations. The overall aim of the research is to characterize the treatment profile, including its relationship to changes in biological markers.

Findings in Specific Patient Groups

Clinical trials have evaluated the treatment across diverse settings. One major area of investigation involves subjects with a specific hematologic disorder.

Study Design: The majority of studies utilized randomized, controlled designs over periods ranging from 4 to 12 weeks, with follow-up extending up to 6 months.
Key Results: Data from a pooled analysis suggested that, when compared to the control group, the treated cohort showed an association with an observed shift in the primary measure. However, findings across all centers were not fully consistent.

Safety and Administration

Safety data were collected across all major studies, detailing common and less common occurrences. The research also investigated different administration protocols to understand their effect on the patient experience. Long-term studies are ongoing to further characterize the complete profile of the treatment.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about WinRho (FAQ)

Q: What is the difference between WinRho and other Rh immune globulin products?

WinRho SDF is a specific preparation of Rho(D) Immune Globulin. Official product information notes that this brand is differentiated by its unique manufacturing process, which includes a dedicated step for virus filtration.

Q: Why is WinRho given routinely around 28 weeks of pregnancy?

Official guidelines recommend routine prophylaxis between 26 and 28 weeks of gestation. This timing is intended to help maintain passive antibody levels throughout the remainder of the pregnancy.

Q: What are the pregnancy-related events where WinRho administration might be needed?

The medicine is indicated for non-sensitized Rh-negative women in various obstetric situations. This includes procedures such as amniocentesis or chorionic villus sampling, as well as events like ectopic pregnancy or spontaneous or induced abortion after 12 weeks of gestation.

Q: What are the key differences between WinRho and IVIG as treatments for ITP?

WinRho SDF is indicated for Immune Thrombocytopenic Purpura (ITP) only in patients who are Rh-positive and non-splenectomized, a specific requirement that differs from Intravenous Immune Globulin (IVIG). Official safety information notes that WinRho SDF carries the specific and serious risk of Intravascular Hemolysis (IVH), a documented risk for this product when used for ITP.

Q: Why is it necessary to be monitored in a clinic for 8 hours after receiving WinRho for ITP?

Regulatory documents state that patients treated for ITP must be monitored closely for at least eight hours following administration. This close observation is required to detect early signs of a serious reaction called Intravascular Hemolysis (IVH).

Q: Is it normal to have dark or reddish-brown urine after an ITP treatment with WinRho?

The product labeling requires patients to be aware of certain signs of Intravascular Hemolysis (IVH). These signs can include discolored urine or hematuria (blood in the urine), which is why patients are instructed to monitor this.

Q: What are the symptoms of intravascular hemolysis (IVH) that require immediate medical attention after treatment?

Official prescribing information advises patients to monitor for symptoms of IVH, which include back pain, shaking chills, and fever. Discolored urine or hematuria are also noted as signs that should be reported immediately.

Q: What is the general expectation for how long the effects of WinRho last for Rh immunization prevention?

When used for routine Rh prophylaxis during pregnancy, a dose is designed to maintain effective anti-D antibody levels for approximately 12 weeks. A repeat dose may be indicated after this period to help maintain protection.

Q: How does WinRho protect a baby from Rh hemolytic disease?

The medicine works by preventing the formation of the mother’s permanent antibodies. By preventing the formation of these maternal anti-D antibodies, the medicine helps minimize the risk of the mother’s immune system attacking the Rh-positive red blood cells of the fetus or newborn, thereby mitigating the potential for severe complications.

Q: Does WinRho protect the current pregnancy or only future ones?

Regulatory indications state that the medicine is given to provide protection for both the current and future pregnancies. Its action is designed to prevent the mother from becoming sensitized during the current pregnancy while also helping to prevent the formation of permanent, long-lasting antibodies that could affect subsequent pregnancies.

Q: Is it true that WinRho is not needed if the baby's father is also Rh-negative?

Official information indicates that the product is needed only when an Rh-negative person is exposed to Rh-positive red blood cells. If the father is confirmed to be Rh-negative, the fetus is expected to be Rh-negative, and prophylaxis is generally not required.

Q: Why is the dosage for Rh prophylaxis different from the dosage for ITP treatment?

Dosage is determined by the treatment's goal. The fixed dosage for Rh prophylaxis is based on neutralizing a small, standard volume of fetal blood exposure. In contrast, the higher, weight-based dosage for ITP is intended to coat the recipient's own Rh-positive red blood cells to achieve a larger scale immune blockade.

Q: Is WinRho safe to take if a person is breastfeeding?

Official information derived from studies indicates that the medicine is generally considered to pose minimal known risk to the infant when used during breastfeeding. The antibodies that pass into breast milk are typically partially destroyed in the infant’s gastrointestinal tract and are poorly absorbed.

Q: How is a doctor able to determine the necessary dose of WinRho after a large bleed during pregnancy?

In cases of suspected large bleeds, known as fetal-maternal hemorrhage (FMH), the doctor must use specialized quantitative tests. The official prescribing information states that tests like the Kleihauer-Betke test are used to measure the estimated volume of fetal cells present, allowing the correct dose to be calculated.

Q: What is the reason a person must be Rh-positive to receive WinRho for ITP?

The medicine is composed of anti-D antibodies that require the D antigen as their target to work. Because the D antigen is found on Rh-positive red blood cells, official product information indicates that if a patient is Rh-negative, the medicine would lack its necessary target and therefore cannot be effective for raising the platelet count in ITP.

Q: How often might a person with chronic ITP receive WinRho treatment?

The official product information states that subsequent doses for chronic ITP are not fixed. The frequency is determined by the healthcare provider based on the patient's individual clinical response, which is assessed by monitoring platelet counts and other blood cell levels.

Q: Can WinRho be used for ITP in a patient who has a history of bleeding disorders?

The product is used in ITP to prevent excessive hemorrhage, but regulatory documents require caution for patients at risk of blood clotting issues. Serious complications such as Disseminated Intravascular Coagulation (DIC), which affects clotting, are noted as possible adverse events.

Q: Does WinRho interact with any routine vaccines, such as the MMR or flu shot?

Regulatory information indicates that the medicine may impair the effectiveness of live virus vaccines (like MMR), which should be delayed for at least three months. However, there is generally minimal or no interaction with inactivated vaccines, like the standard flu shot.

Q: What is the risk of a lung problem called TRALI after receiving immune globulin products like WinRho?

Official warnings state that a serious lung condition called Transfusion-related Acute Lung Injury (TRALI) may occur in patients following treatment with WinRho SDF. TRALI is a type of noncardiogenic pulmonary edema that has been documented with this and other Immune Globulin products.

Q: Is it recommended to receive pre-medication before a WinRho infusion?

Pre-medications, such as antihistamines or fever reducers, are generally not mandatory according to official prescribing information. They may be administered only at the discretion of the healthcare provider.

Q: Why is the color of urine often monitored after WinRho is given for ITP?

Monitoring urine color is required because it is a patient-visible sign of Intravascular Hemolysis (IVH). The official labeling requires monitoring for signs of discolored urine or hematuria.

Q: Is the risk of side effects generally different between the IV infusion compared to the IM injection?

The official safety profile notes that the most serious risk, Intravascular Hemolysis (IVH), is associated with the intravenous (IV) route when the medicine is used for ITP treatment. The intramuscular (IM) route is not an approved option for ITP.

How should WinRho be stored and disposed of?

How to Store and Dispose of WinRho

WinRho SDF (Rho(D) Immune Globulin (Human)) must be stored according to strict regulatory requirements to maintain the stability of the product.

Storage Requirements

The product must be stored under refrigeration at a temperature range of 2 C to 8 C (36 F to 46 F). It is mandatory that the medicine must not be frozen. The vials must be kept in their original container to protect the contents from light.

Stability and Handling

WinRho SDF should not be used past the expiration date printed on the label. Once prepared for administration, the infusion must be completed within four hours.

Disposal Instructions

Keep the medicine out of the sight and reach of children. Any unused or expired product and related waste materials must be disposed of in accordance with local regulations for pharmaceutical and biological waste.

WinRho